EUCTR2021-000300-38-BE进行中（未招募）1 期
Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) - B-VOICE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age of 18 years or older
- •Patients should meet one of the cohort criteria
- •Life expectancy > 12 months
- •Ability to provide informed consent
- •ADDENDUM extra booster shot
- •Former participant of the B-VOICE study
- •Vaccinated with priming and boosting BNT162b2 vaccine
- •Ability to provide informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Women who are pregnant or breastfeeding
- •Immune deficiency not related to cancer or cancer treatment
- •Systemic treatment with immune suppressive medication, including chronic steroid use of >10 mg prednisone or equivalent
研究者
相似试验
进行中（未招募）
1 期
Vaccination against cOvid In CancErsolid tumorsEUCTR2021-000872-13-NLniversity Medical Center Groningen873
招募中
不适用
Vaccination against cOvid In CancErNL-OMON52037niversitair Medisch Centrum Groningen873
进行中（未招募）
1 期
sing one dose Pfizer to boost immunity after full vaccination with AstraZeneca in cancer patientsOnco-hematological patientsEUCTR2021-003573-58-BEAntwerp University Hospital182
已完成
不适用
Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer PatientsMalignancies MultipleNCT04953065Monika Joshi130
进行中（未招募）
1 期
COVID-19 :Immune response in patients with cancer undergoing vaccination against SARS-CoV-2adult cancer patientsMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003710-39-BEINSTITUT JULES BORDET440